What do systematic reviews say?

Maintenance treatment with antipsychotic drugs vs placebo/no treatment

Maintenance treatment with antipsychotic drugs leads to lower leaving the study early: due to any reason (acceptability of… compared with placebo/no treatment (high certainty).

• Maintenance treatment with antipsychotic drugs for schizophrenia 2020 · Cochrane Headline outcomes only
  RR 0.54 [0.49, 0.61]
  56 studies · 7001 participants
  High

FLUPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

FLUPHENAZINE showed no clear difference in acceptability of treatment‐leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).

• Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 1 [0.88, 1.14]
  6 studies · 1532 participants
  Moderate

PERPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

It is very uncertain whether comparison 1: PERPHENAZINE changes acceptability of treatment ‐ leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).

• Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 0.78 [0.35, 1.76]
  3 studies · 323 participants
  Very low

TRIFLUOPERAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Trifluoperazine showed no clear difference in leaving the study early: 1. Acceptability of treatment ‐ leaving… compared with low‐potency antipsychotic drugs (low certainty).

• Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 1.25 [0.72, 2.17]
  3 studies · 239 participants
  Low

FLUPENTHIXOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

• Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported